{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:56:34Z","timestamp":1785473794694,"version":"3.56.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00415-025-13499-x","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T10:24:00Z","timestamp":1766399040000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Serum and cerebrospinal fluid biomarkers as predictors of cognitive impairment in multiple sclerosis: a systematic review of longitudinal studies"],"prefix":"10.1007","volume":"273","author":[{"given":"Giovanni","family":"Restuccia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2507-6606","authenticated-orcid":false,"given":"Carla","family":"Susinna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Marafioti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Rifici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giangaetano","family":"D\u2019Aleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Sessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Silvestro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Quartarone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Lo Buono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"key":"13499_CR1","doi-asserted-by":"publisher","first-page":"e37297","DOI":"10.1097\/MD.0000000000037297","volume":"103","author":"M Haki","year":"2024","unstructured":"Haki M, AL-Biati HA, Al-Tameemi ZS, Ali IS, Al-hussaniy HA (2024) Review of multiple sclerosis: epidemiology, etiology, pathophysiology, and treatment. Medicine (Baltimore) 103:e37297. https:\/\/doi.org\/10.1097\/MD.0000000000037297","journal-title":"Medicine (Baltimore)"},{"key":"13499_CR2","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1001\/jama.2020.26858","volume":"325","author":"MP McGinley","year":"2021","unstructured":"McGinley MP, Goldschmidt CH, Rae-Grant AD (2021) Diagnosis and treatment of multiple sclerosis: a review. JAMA 325:765\u2013779. https:\/\/doi.org\/10.1001\/jama.2020.26858","journal-title":"JAMA"},{"key":"13499_CR3","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","volume":"26","author":"C Walton","year":"2020","unstructured":"Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA et al (2020) Rising prevalence of multiple sclerosis worldwide: insights from the atlas of MS, third edition. Mult Scler J 26:1816\u20131821. https:\/\/doi.org\/10.1177\/1352458520970841","journal-title":"Mult Scler J"},{"key":"13499_CR4","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1093\/brain\/awac111","volume":"145","author":"E Portaccio","year":"2022","unstructured":"Portaccio E, Bellinvia A, Fonderico M, Past\u00f2 L, Razzolini L, Totaro R et al (2022) Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study. Brain J Neurol 145:2796\u20132805. https:\/\/doi.org\/10.1093\/brain\/awac111","journal-title":"Brain J Neurol"},{"key":"13499_CR5","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/S1474-4422(08)70259-X","volume":"7","author":"ND Chiaravalloti","year":"2008","unstructured":"Chiaravalloti ND, DeLuca J (2008) Cognitive impairment in multiple sclerosis. Lancet Neurol 7:1139\u20131151. https:\/\/doi.org\/10.1016\/S1474-4422(08)70259-X","journal-title":"Lancet Neurol"},{"key":"13499_CR6","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1212\/WNL.41.5.692","volume":"41","author":"SM Rao","year":"1991","unstructured":"Rao SM, Leo GJ, Ellington L, Nauertz T, Bernardin L, Unverzagt F (1991) Cognitive dysfunction in multiple sclerosis. Neurology 41:692\u2013696. https:\/\/doi.org\/10.1212\/WNL.41.5.692","journal-title":"Neurology"},{"key":"13499_CR7","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1080\/00207454.2021.1879066","volume":"132","author":"T Doskas","year":"2022","unstructured":"Doskas T, Vavougios GD, Karampetsou P, Kormas C, Synadinakis E, Stavrogianni K et al (2022) Neurocognitive impairment and social cognition in multiple sclerosis. Int J Neurosci 132:1229\u20131244. https:\/\/doi.org\/10.1080\/00207454.2021.1879066","journal-title":"Int J Neurosci"},{"key":"13499_CR8","doi-asserted-by":"publisher","first-page":"110990","DOI":"10.1016\/j.jocn.2024.110990","volume":"132","author":"S Daneshvar","year":"2025","unstructured":"Daneshvar S, Moradi F, Rahmani M, Golshaniniya P, Frounchi N, Seifimansour S et al (2025) Association of serum levels of inflammation and oxidative stress markers with cognitive outcomes in multiple sclerosis: a systematic review. J Clin Neurosci 132:110990. https:\/\/doi.org\/10.1016\/j.jocn.2024.110990","journal-title":"J Clin Neurosci"},{"key":"13499_CR9","doi-asserted-by":"publisher","first-page":"e44826","DOI":"10.1371\/journal.pone.0044826","volume":"7","author":"F Rossi","year":"2012","unstructured":"Rossi F, Giorgio A, Battaglini M, Stromillo ML, Portaccio E, Goretti B et al (2012) Relevance of brain lesion location to cognition in relapsing multiple sclerosis. PLoS ONE 7:e44826. https:\/\/doi.org\/10.1371\/journal.pone.0044826","journal-title":"PLoS ONE"},{"key":"13499_CR10","doi-asserted-by":"publisher","first-page":"105035","DOI":"10.1016\/j.neubiorev.2023.105035","volume":"146","author":"T-D Rademacher","year":"2023","unstructured":"Rademacher T-D, Meuth SG, Wiendl H, Johnen A, Landmeyer NC (2023) Molecular biomarkers and cognitive impairment in multiple sclerosis: state of the field, limitations, and future direction: a systematic review and meta-analysis. Neurosci Biobehav Rev 146:105035. https:\/\/doi.org\/10.1016\/j.neubiorev.2023.105035","journal-title":"Neurosci Biobehav Rev"},{"key":"13499_CR11","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1176\/appi.ajp.2021.19080873","volume":"178","author":"A Kumar","year":"2021","unstructured":"Kumar A, Nemeroff CB, Cooper JJ, Widge A, Rodriguez C, Carpenter L et al (2021) Amyloid and tau in Alzheimer\u2019s disease: biomarkers or molecular targets for therapy? Are we shooting the messenger? Am J Psychiatry 178:1014\u20131025. https:\/\/doi.org\/10.1176\/appi.ajp.2021.19080873","journal-title":"Am J Psychiatry"},{"key":"13499_CR12","doi-asserted-by":"publisher","first-page":"100074","DOI":"10.1016\/j.bionps.2023.100074","volume":"9","author":"KY Yamashita","year":"2023","unstructured":"Yamashita KY, Bhoopatiraju S, Silverglate BD, Grossberg GT (2023) Biomarkers in Parkinson\u2019s disease: a state of the art review. Biomark Neuropsychiatry 9:100074. https:\/\/doi.org\/10.1016\/j.bionps.2023.100074","journal-title":"Biomark Neuropsychiatry"},{"key":"13499_CR13","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"13499_CR14","doi-asserted-by":"publisher","first-page":"108602","DOI":"10.1016\/j.envint.2024.108602","volume":"186","author":"JPT Higgins","year":"2024","unstructured":"Higgins JPT, Morgan RL, Rooney AA, Taylor KW, Thayer KA, Silva RA et al (2024) A tool to assess risk of bias in non-randomized follow-up studies of exposure effects (ROBINS-E). Environ Int 186:108602. https:\/\/doi.org\/10.1016\/j.envint.2024.108602","journal-title":"Environ Int"},{"key":"13499_CR15","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1177\/13524585221137697","volume":"29","author":"C Barro","year":"2023","unstructured":"Barro C, Healy BC, Saxena S, Glanz BI, Paul A, Polgar-Turcsanyi M et al (2023) Serum NfL but not GFAP predicts cognitive decline in active progressive multiple sclerosis patients. Mult Scler J 29:206\u2013211. https:\/\/doi.org\/10.1177\/13524585221137697","journal-title":"Mult Scler J"},{"key":"13499_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2023\/7136599","volume":"2023","author":"A Bhan","year":"2023","unstructured":"Bhan A, Jacobsen C, Dalen I, Alves G, Bergsland N, Myhr K-M et al (2023) Neurofilament and brain atrophy and their association with cognition in multiple sclerosis: a 10-year follow-up study. Acta Neurol Scand 2023:1\u201310. https:\/\/doi.org\/10.1155\/2023\/7136599","journal-title":"Acta Neurol Scand"},{"key":"13499_CR17","doi-asserted-by":"publisher","first-page":"10012","DOI":"10.3390\/ijms251810012","volume":"25","author":"M Dom\u00ednguez-Mozo","year":"2024","unstructured":"Dom\u00ednguez-Mozo M, Casanova I, Monreal E, Costa-Frossard L, Sainz-de-la-Maza S, Sainz-Amo R et al (2024) Association of microRNA expression and serum neurofilament light chain levels with clinical and radiological findings in multiple sclerosis. Int J Mol Sci 25:10012. https:\/\/doi.org\/10.3390\/ijms251810012","journal-title":"Int J Mol Sci"},{"key":"13499_CR18","doi-asserted-by":"publisher","first-page":"102534","DOI":"10.1016\/j.msard.2020.102534","volume":"46","author":"L Friedova","year":"2020","unstructured":"Friedova L, Motyl J, Srpova B, Oechtering J, Barro C, Vodehnalova K et al (2020) The weak association between neurofilament levels at multiple sclerosis onset and cognitive performance after 9 years. Mult Scler Relat Disord 46:102534. https:\/\/doi.org\/10.1016\/j.msard.2020.102534","journal-title":"Mult Scler Relat Disord"},{"key":"13499_CR19","doi-asserted-by":"publisher","first-page":"1223220","DOI":"10.3389\/fneur.2023.1223220","volume":"14","author":"M Oset","year":"2023","unstructured":"Oset M, Domowicz M, Wildner P, Siger M, Karli\u0144ska I, Stasio\u0142ek M et al (2023) Predictive value of brain atrophy, serum biomarkers and information processing speed for early disease progression in multiple sclerosis. Front Neurol 14:1223220. https:\/\/doi.org\/10.3389\/fneur.2023.1223220","journal-title":"Front Neurol"},{"key":"13499_CR20","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.3390\/diagnostics12112571","volume":"12","author":"VE Tiu","year":"2022","unstructured":"Tiu VE, Popescu BO, Enache II, Tiu C, Terecoasa E, Panea CA (2022) Serum and CSF biomarkers predict active early cognitive decline rather than established cognitive impairment at the moment of RRMS diagnosis. Diagnostics 12:2571. https:\/\/doi.org\/10.3390\/diagnostics12112571","journal-title":"Diagnostics"},{"key":"13499_CR21","doi-asserted-by":"publisher","first-page":"104567","DOI":"10.1016\/j.msard.2023.104567","volume":"71","author":"Y Yalachkov","year":"2023","unstructured":"Yalachkov Y, Ansch\u00fctz V, Maiworm M, Jakob J, Schaller-Paule MA, Sch\u00e4fer JH et al (2023) Serum and cerebrospinal fluid BDNF concentrations are associated with neurological and cognitive improvement in multiple sclerosis: a pilot study. Mult Scler Relat Disord 71:104567. https:\/\/doi.org\/10.1016\/j.msard.2023.104567","journal-title":"Mult Scler Relat Disord"},{"key":"13499_CR22","doi-asserted-by":"publisher","first-page":"e200301","DOI":"10.1212\/NXI.0000000000200301","volume":"11","author":"S Ziccardi","year":"2024","unstructured":"Ziccardi S, Tamanti A, Ruggieri C, Guandalini M, Marastoni D, Camera V et al (2024) CSF parvalbumin levels at multiple sclerosis diagnosis predict future worse cognition, physical disability, fatigue, and gray matter damage. Neurol Neuroimmunol Neuroinflamm 11:e200301. https:\/\/doi.org\/10.1212\/NXI.0000000000200301","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13499_CR23","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s13643-018-0915-2","volume":"7","author":"L Bero","year":"2018","unstructured":"Bero L, Chartres N, Diong J, Fabbri A, Ghersi D, Lam J et al (2018) The risk of bias in observational studies of exposures (ROBINS-E) tool: concerns arising from application to observational studies of exposures. Syst Rev 7:242. https:\/\/doi.org\/10.1186\/s13643-018-0915-2","journal-title":"Syst Rev"},{"key":"13499_CR24","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","volume":"14","author":"M Khalil","year":"2018","unstructured":"Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T et al (2018) Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 14:577\u2013589. https:\/\/doi.org\/10.1038\/s41582-018-0058-z","journal-title":"Nat Rev Neurol"},{"key":"13499_CR25","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1093\/brain\/awy154","volume":"141","author":"C Barro","year":"2018","unstructured":"Barro C, Benkert P, Disanto G, Tsagkas C, Amann M, Naegelin Y et al (2018) Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain 141:2382\u20132391. https:\/\/doi.org\/10.1093\/brain\/awy154","journal-title":"Brain"},{"key":"13499_CR26","doi-asserted-by":"publisher","first-page":"e2700","DOI":"10.1002\/brb3.2700","volume":"12","author":"T Williams","year":"2022","unstructured":"Williams T, Heslegrave A, Zetterberg H, Miszkiel KA, Barkhof F, Ciccarelli O et al (2022) The prognostic significance of early blood neurofilament light chain concentration and magnetic resonance imaging variables in relapse-onset multiple sclerosis. Brain Behav 12:e2700. https:\/\/doi.org\/10.1002\/brb3.2700","journal-title":"Brain Behav"},{"key":"13499_CR27","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1007\/s00415-019-09398-7","volume":"266","author":"L Gaetani","year":"2019","unstructured":"Gaetani L, Salvadori N, Lisetti V, Eusebi P, Mancini A, Gentili L et al (2019) Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis. J Neurol 266:2157\u20132163. https:\/\/doi.org\/10.1007\/s00415-019-09398-7","journal-title":"J Neurol"},{"key":"13499_CR28","doi-asserted-by":"publisher","first-page":"1255263","DOI":"10.1126\/science.1255263","volume":"345","author":"H Hu","year":"2014","unstructured":"Hu H, Gan J, Jonas P (2014) Interneurons. Fast-spiking, parvalbumin+ GABAergic interneurons: from cellular design to microcircuit function. Science 345:1255263. https:\/\/doi.org\/10.1126\/science.1255263","journal-title":"Science"},{"key":"13499_CR29","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/acn3.51298","volume":"8","author":"R Magliozzi","year":"2021","unstructured":"Magliozzi R, Pitteri M, Ziccardi S, Pisani AI, Montibeller L, Marastoni D et al (2021) CSF parvalbumin levels reflect interneuron loss linked with cortical pathology in multiple sclerosis. Ann Clin Transl Neurol 8:534\u2013547. https:\/\/doi.org\/10.1002\/acn3.51298","journal-title":"Ann Clin Transl Neurol"},{"key":"13499_CR30","doi-asserted-by":"publisher","first-page":"45284","DOI":"10.1038\/srep45284","volume":"7","author":"C Cerutti","year":"2017","unstructured":"Cerutti C, Edwards LJ, de Vries HE, Sharrack B, Male DK, Romero IA (2017) MiR-126 and miR-126* regulate shear-resistant firm leukocyte adhesion to human brain endothelium. Sci Rep 7:45284. https:\/\/doi.org\/10.1038\/srep45284","journal-title":"Sci Rep"},{"key":"13499_CR31","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1161\/STROKEAHA.119.027531","volume":"51","author":"J Pan","year":"2020","unstructured":"Pan J, Qu M, Li Y, Wang L, Zhang L, Wang Y et al (2020) Microrna-126-3p\/-5p overexpression attenuates blood-brain barrier disruption in a mouse model of middle cerebral artery occlusion. Stroke 51:619\u2013627. https:\/\/doi.org\/10.1161\/STROKEAHA.119.027531","journal-title":"Stroke"},{"key":"13499_CR32","doi-asserted-by":"publisher","first-page":"4386","DOI":"10.1038\/ncomms5386","volume":"5","author":"H Yao","year":"2014","unstructured":"Yao H, Ma R, Yang L, Hu G, Chen X, Duan M et al (2014) MiR-9 promotes microglial activation by targeting MCPIP1. Nat Commun 5:4386. https:\/\/doi.org\/10.1038\/ncomms5386","journal-title":"Nat Commun"},{"key":"13499_CR33","doi-asserted-by":"publisher","first-page":"e14963","DOI":"10.1111\/jnc.14963","volume":"153","author":"J Wu","year":"2020","unstructured":"Wu J, He J, Tian X, Luo Y, Zhong J, Zhang H et al (2020) Microrna-9-5p alleviates blood\u2013brain barrier damage and neuroinflammation after traumatic brain injury. J Neurochem 153:e14963. https:\/\/doi.org\/10.1111\/jnc.14963","journal-title":"J Neurochem"},{"key":"13499_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2019.00363","author":"M Miranda","year":"2019","unstructured":"Miranda M, Morici JF, Zanoni MB, Bekinschtein P, Frontiers (2019) Brain-derived neurotrophic factor: a key molecule for memory in the healthy and the pathological brain. Front Cell Neurosci. https:\/\/doi.org\/10.3389\/fncel.2019.00363","journal-title":"Front Cell Neurosci"},{"key":"13499_CR35","doi-asserted-by":"publisher","first-page":"14798","DOI":"10.1038\/s41598-018-33158-8","volume":"8","author":"A Abdelhak","year":"2018","unstructured":"Abdelhak A, Huss A, Kassubek J, Tumani H, Otto M (2018) Serum GFAP as a biomarker for disease severity in multiple sclerosis. Sci Rep 8:14798. https:\/\/doi.org\/10.1038\/s41598-018-33158-8","journal-title":"Sci Rep"},{"key":"13499_CR36","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1177\/1352458518819380","volume":"26","author":"H H\u00f6gel","year":"2020","unstructured":"H\u00f6gel H, Rissanen E, Barro C, Matilainen M, Nylund M, Kuhle J et al (2020) Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity. Mult Scler J 26:210\u2013219. https:\/\/doi.org\/10.1177\/1352458518819380","journal-title":"Mult Scler J"},{"key":"13499_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-023-00447-7","volume":"9","author":"Y Tang","year":"2023","unstructured":"Tang Y, Han L, Li S, Hu T, Xu Z, Fan Y et al (2023) Plasma GFAP in Parkinson\u2019s disease with cognitive impairment and its potential to predict conversion to dementia. NPJ Parkinsons Dis 9:23. https:\/\/doi.org\/10.1038\/s41531-023-00447-7","journal-title":"NPJ Parkinsons Dis"},{"key":"13499_CR38","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1177\/1352458510389102","volume":"17","author":"M Khademi","year":"2011","unstructured":"Khademi M, Kockum I, Andersson ML, Iacobaeus E, Brundin L, Sellebjerg F et al (2011) Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult Scler J 17:335\u2013343. https:\/\/doi.org\/10.1177\/1352458510389102","journal-title":"Mult Scler J"},{"key":"13499_CR39","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3390\/genes13050897","volume":"13","author":"A Bruno","year":"2022","unstructured":"Bruno A, Dolcetti E, Azzolini F, Moscatelli A, Gambardella S, Ferese R et al (2022) Interleukin 6 SNP rs1818879 regulates radiological and inflammatory activity in multiple sclerosis. Genes 13:897. https:\/\/doi.org\/10.3390\/genes13050897","journal-title":"Genes"},{"key":"13499_CR40","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1007\/s10072-023-06764-2","volume":"44","author":"F Talaat","year":"2023","unstructured":"Talaat F, Abdelatty S, Ragaie C, Dahshan A (2023) Chitinase-3-like 1-protein in CSF: a novel biomarker for progression in patients with multiple sclerosis. Neurol Sci 44:3243\u20133252. https:\/\/doi.org\/10.1007\/s10072-023-06764-2","journal-title":"Neurol Sci"},{"key":"13499_CR41","doi-asserted-by":"publisher","first-page":"e200265","DOI":"10.1212\/NXI.0000000000200265","volume":"11","author":"D Marastoni","year":"2024","unstructured":"Marastoni D, Turano E, Tamanti A, Colato E, Pisani AI, Scartezzini A et al (2024) Association of levels of CSF osteopontin with cortical atrophy and disability in early multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 11:e200265. https:\/\/doi.org\/10.1212\/NXI.0000000000200265","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13499_CR42","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","volume":"21","author":"P Benkert","year":"2022","unstructured":"Benkert P, Meier S, Schaedelin S, Manouchehrinia A, Yaldizli \u00d6, Maceski A et al (2022) Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurol 21:246\u2013257. https:\/\/doi.org\/10.1016\/S1474-4422(22)00009-6","journal-title":"Lancet Neurol"},{"key":"13499_CR43","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nbt.1641","volume":"28","author":"DM Rissin","year":"2010","unstructured":"Rissin DM, Kan CW, Campbell TG, Howes SC, Fournier DR, Song L et al (2010) Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol 28:595\u2013599. https:\/\/doi.org\/10.1038\/nbt.1641","journal-title":"Nat Biotechnol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13499-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13499-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13499-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T12:57:24Z","timestamp":1773665844000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13499-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["13499"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13499-x","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,22]]},"assertion":[{"value":"16 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"36"}}